View in EDS

AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.

Saved in:
Bibliographic Details
Title: AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.
Authors: Doffman SR; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass. Electronic address: sarah.doffman@astrazeneca.com., Dosanjh DPS; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass; Birmingham Acute Care Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom., Sadiq MW; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Matsunaga Y; Global Development, Inflammation, R&D, Amgen Inc., Thousand Oaks, Calif., Cooper JD; Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Edwards G; Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Asimus S; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Abuqayyas L; Clinical Pharmacology Modeling and Simulation, Amgen, Cambridge, Mass., Zhou XH; Patient Safety Biopharma, Chief Medical Office, Oncology R&D, AstraZeneca, Gothenburg, Sweden., Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Cardner M; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Parnes JR; Early Development, Amgen Inc., Thousand Oaks, Calif., Kovacina K; Bioanalysis, AstraZeneca, San Francisco, Calif., White N; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, Mass., Cushion MG; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass., Belvisi MG; Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Respiratory Pharmacology, National Heart and Lung Institute, Imperial College London, London, United Kingdom., Saralaya D; Respiratory Medicine, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom., Brown T; Respiratory Medicine, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom., Beier J; Insaf Respiratory Research Institute, Taunusstein, Germany., Molfino NA; Global Development, Inflammation, R&D, Amgen Inc., Thousand Oaks, Calif.
Source: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2026 Apr 20. Date of Electronic Publication: 2026 Apr 20.
Publication Type: Journal Article
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825 (Electronic) Linking ISSN: 00916749 NLM ISO Abbreviation: J Allergy Clin Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42019634
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Doffman+SR%22">Doffman SR</searchLink>; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass. Electronic address: sarah.doffman@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Dosanjh+DPS%22">Dosanjh DPS</searchLink>; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass; Birmingham Acute Care Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Sadiq+MW%22">Sadiq MW</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Matsunaga+Y%22">Matsunaga Y</searchLink>; Global Development, Inflammation, R&D, Amgen Inc., Thousand Oaks, Calif.<br /><searchLink fieldCode="AU" term="%22Cooper+JD%22">Cooper JD</searchLink>; Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass.<br /><searchLink fieldCode="AU" term="%22Edwards+G%22">Edwards G</searchLink>; Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass.<br /><searchLink fieldCode="AU" term="%22Asimus+S%22">Asimus S</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Abuqayyas+L%22">Abuqayyas L</searchLink>; Clinical Pharmacology Modeling and Simulation, Amgen, Cambridge, Mass.<br /><searchLink fieldCode="AU" term="%22Zhou+XH%22">Zhou XH</searchLink>; Patient Safety Biopharma, Chief Medical Office, Oncology R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Scott+IC%22">Scott IC</searchLink>; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass.<br /><searchLink fieldCode="AU" term="%22Cardner+M%22">Cardner M</searchLink>; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Parnes+JR%22">Parnes JR</searchLink>; Early Development, Amgen Inc., Thousand Oaks, Calif.<br /><searchLink fieldCode="AU" term="%22Kovacina+K%22">Kovacina K</searchLink>; Bioanalysis, AstraZeneca, San Francisco, Calif.<br /><searchLink fieldCode="AU" term="%22White+N%22">White N</searchLink>; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, Mass.<br /><searchLink fieldCode="AU" term="%22Cushion+MG%22">Cushion MG</searchLink>; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, Mass.<br /><searchLink fieldCode="AU" term="%22Belvisi+MG%22">Belvisi MG</searchLink>; Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Respiratory Pharmacology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Saralaya+D%22">Saralaya D</searchLink>; Respiratory Medicine, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Brown+T%22">Brown T</searchLink>; Respiratory Medicine, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Beier+J%22">Beier J</searchLink>; Insaf Respiratory Research Institute, Taunusstein, Germany.<br /><searchLink fieldCode="AU" term="%22Molfino+NA%22">Molfino NA</searchLink>; Global Development, Inflammation, R&D, Amgen Inc., Thousand Oaks, Calif.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%221275002%22">The Journal of allergy and clinical immunology</searchLink> [J Allergy Clin Immunol] 2026 Apr 20. <i>Date of Electronic Publication: </i>2026 Apr 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mosby%22">Mosby </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>1275002 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-6825 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200916749%22">00916749 </searchLink><i>NLM ISO Abbreviation: </i>J Allergy Clin Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42019634
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jaci.2026.03.026
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Doffman SR
      – PersonEntity:
          Name:
            NameFull: Dosanjh DPS
      – PersonEntity:
          Name:
            NameFull: Sadiq MW
      – PersonEntity:
          Name:
            NameFull: Matsunaga Y
      – PersonEntity:
          Name:
            NameFull: Cooper JD
      – PersonEntity:
          Name:
            NameFull: Edwards G
      – PersonEntity:
          Name:
            NameFull: Asimus S
      – PersonEntity:
          Name:
            NameFull: Abuqayyas L
      – PersonEntity:
          Name:
            NameFull: Zhou XH
      – PersonEntity:
          Name:
            NameFull: Scott IC
      – PersonEntity:
          Name:
            NameFull: Cardner M
      – PersonEntity:
          Name:
            NameFull: Parnes JR
      – PersonEntity:
          Name:
            NameFull: Kovacina K
      – PersonEntity:
          Name:
            NameFull: White N
      – PersonEntity:
          Name:
            NameFull: Cushion MG
      – PersonEntity:
          Name:
            NameFull: Belvisi MG
      – PersonEntity:
          Name:
            NameFull: Saralaya D
      – PersonEntity:
          Name:
            NameFull: Brown T
      – PersonEntity:
          Name:
            NameFull: Beier J
      – PersonEntity:
          Name:
            NameFull: Molfino NA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 04
              Text: 2026 Apr 20
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1097-6825
          Titles:
            – TitleFull: The Journal of allergy and clinical immunology
              Type: main
ResultId 1